Selegiline reverses Aβ25-35-induced cognitive deficit in male mice

Neurochemical Research

Volumn 38, Issue 11, 2013, Pages 2287-2294

  Pazini, Andréia M ^a   Gomes, Guilherme M ^a   Villarinho, Jardel G ^a   Da Cunha, Claudio ^b   Pinheiro, Francielle ^a   Ferreira, Ana P O ^a   Mello, Carlos F ^a   Ferreira, Juliano ^a   Rubin, Maribel A ^a  

^a FEDERAL UNIVERSITY OF SANTA MARIA   (Brazil)

^b FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

Author keywords

Alzheimer's disease; MAO inhibitors; MAO B; Memory; Object recognition; Perirhinal cortex

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; SELEGILINE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN CORTEX; COGNITIVE DEFECT; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; ENZYME ACTIVITY; EX VIVO STUDY; HIPPOCAMPUS; IN VIVO STUDY; MALE; MENTAL TASK; MONOAMINERGIC SYSTEM; MOUSE; NONHUMAN; PERIRHINAL CORTEX; PRIORITY JOURNAL; RECOGNITION;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; CEREBRAL CORTEX; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; HIPPOCAMPUS; MALE; MICE; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; PEPTIDE FRAGMENTS; SELEGILINE;

EID: 84886908093     PISSN: 03643190     EISSN: 15736903     Source Type: Journal    
DOI: 10.1007/s11064-013-1137-6     Document Type: Article

References (42)

1. Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP (2013) The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Dement 9 (1):63-75 e62
2. Comas-Herrera A, Northey S, Wittenberg R, Knapp M, Bhattacharyya S, Burns A (2011) Future costs of dementia-related long-term care: exploring future scenarios. Int Psychogeriatr 23(1):20-30
3. Desai AK, Grossberg GT (2005) Diagnosis and treatment of Alzheimer's disease. Neurology 64(12 Suppl 3):S34-S39
4. Doody RS (2005) Refining treatment guidelines in Alzheimer's disease. Geriatr Suppl: 14-20
5. Fan LY, Chiu MJ (2010) Pharmacological treatment for Alzheimer's disease: current approaches and future strategies. Acta Neurol Taiwan 19(4):228-245
6. Jenner P (2004) Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson's disease. Neurology 63(7 Suppl 2):S13-S22
7. Waters CH, Sethi KD, Hauser RA, Molho E, Bertoni JM (2004) Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study. Mov Disord 19(4):426-432
8. Pahwa R, Factor SA, Lyons KE, Ondo WG, Gronseth G, Bronte-Stewart H, Hallett M, Miyasaki J, Stevens J, Weiner WJ (2006) Practice parameter: treatment of parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 66(7):983-995
9. Youdim MB, Edmondson D, Tipton KF (2006) The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci 7(4):295-309
10. Reinikainen KJ, Soininen H, Riekkinen PJ (1990) Neurotransmitter changes in Alzheimer's disease: implications to diagnostics and therapy. J Neurosci Res 27(4):576-586
11. Sparks DL, Woeltz VM, Markesbery WR (1991) Alterations in brain monoamine oxidase activity in aging, Alzheimer's disease, and pick's disease. Arch Neurol 48(7):718-721
12. Saura J, Luque JM, Cesura AM, Da Prada M, Chan-Palay V, Huber G, Loffler J, Richards JG (1994) Increased monoamine oxidase B activity in plaque-associated astrocytes of alzheimer brains revealed by quantitative enzyme radioautography. Neuroscience 62(1):15-30
13. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, Woodbury P, Growdon J, Cotman CW, Pfeiffer E, Schneider LS, Thal LJ (1997) A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. the Alzheimer's disease cooperative study. N Engl J Med 336(17):1216-1222
14. Thomas T (2000) Monoamine oxidase-B inhibitors in the treatment of Alzheimer's disease. Neurobiol Aging 21(2):343-348
15. Wilcock GK, Birks J, Whitehead A, Evans SJ (2002) The effect of selegiline in the treatment of people with Alzheimer's disease: a meta-analysis of published trials. Int J Geriatr Psychiatry 17(2):175-183
16. Haley TJ, McCormick WG (1957) Pharmacological effects produced by intracerebral injection of drugs in the conscious mouse. Br J Pharmacol Chemother 12(1):12-15
17. Antunes M, Biala G The novel object recognition memory: neurobiology, test procedure, and its modifications. Cogn Process 13 (2):93-110
18. Wang D, Noda Y, Zhou Y, Mouri A, Mizoguchi H, Nitta A, Chen W, Nabeshima T (2007) The allosteric potentiation of nicotinic acetylcholine receptors by galantamine ameliorates the cognitive dysfunction in beta amyloid25-35 i.c.v.-injected mice: involvement of dopaminergic systems. Neuropsychopharmacology 32(6):1261-1271
19. Nagai T, Yamada K, Kim HC, Kim YS, Noda Y, Imura A, Nabeshima Y, Nabeshima T (2003) Cognition impairment in the genetic model of aging klotho gene mutant mice: a role of oxidative stress. Faseb J 17(1):50-52
20. Kamei H, Nagai T, Nakano H, Togan Y, Takayanagi M, Takahashi K, Kobayashi K, Yoshida S, Maeda K, Takuma K, Nabeshima T, Yamada K (2006) Repeated methamphetamine treatment impairs recognition memory through a failure of novelty-induced ERK1/2 activation in the prefrontal cortex of mice. Biol Psychiatry 59(1):75-84
21. Roozendaal B, Castello NA, Vedana G, Barsegyan A, McGaugh JL (2008) Noradrenergic activation of the basolateral amygdala modulates consolidation of object recognition memory. Neurobiol Learn Mem 90(3):576-579
22. Matsumoto T, Suzuki O, Furuta T, Asai M, Kurokawa Y, Nimura Y, Katsumata Y, Takahashi I (1985) A sensitive fluorometric assay for serum monoamine oxidase with kynuramine as substrate. Clin Biochem 18(2):126-129
23. Sant' Anna Gda S, Machado P, Sauzem PD, Rosa FA, Rubin MA, Ferreira J, Bonacorso HG, Zanatta N, Martins MA (2009) Ultrasound promoted synthesis of 2-imidazolines in water: a greener approach toward monoamine oxidase inhibitors. Bioorg Med Chem Lett 19(2):546-549
24. Villarinho JG, Oliveira SM, Silva CR, Cabreira TN, Ferreira J (2012) Involvement of monoamine oxidase B on models of postoperative and neuropathic pain in mice. Eur J Pharmacol 690(1-3):107-114
25. Tsunekawa H, Noda Y, Mouri A, Yoneda F, Nabeshima T (2008) Synergistic effects of selegiline and donepezil on cognitive impairment induced by amyloid beta (25-35). Behav Brain Res 190(2):224-232
26. Takahata K, Minami A, Kusumoto H, Shimazu S, Yoneda F (2005) Effects of selegiline alone or with donepezil on memory impairment in rats. Eur J Pharmacol 518(2-3):140-144
27. de Lima MN, Laranja DC, Caldana F, Bromberg E, Roesler R, Schroder N (2005) Reversal of age-related deficits in object recognition memory in rats with l-deprenyl. Exp Gerontol 40(6):506-511
28. Filip V, Kolibas E (1999) Selegiline in the treatment of Alzheimer's disease: a long-term randomized placebo-controlled trial. Czech and slovak senile dementia of alzheimer type study group. J Psychiatry Neurosci 24(3):234-243
29. Braak H, Braak E (1991) Neuropathological stageing of alzheimer-related changes. Acta Neuropathol 82(4):239-259
30. Delacourte A, David JP, Sergeant N, Buee L, Wattez A, Vermersch P, Ghozali F, Fallet-Bianco C, Pasquier F, Lebert F, Petit H, Di Menza C (1999) The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer's disease. Neurology 52(6):1158-1165
31. Bevilaqua L, Ardenghi P, Schroder N, Bromberg E, Schmitz PK, Schaeffer E, Quevedo J, Bianchin M, Walz R, Medina JH, Izquierdo I (1997) Drugs acting upon the cyclic adenosine monophosphate/protein kinase a signalling pathway modulate memory consolidation when given late after training into rat hippocampus but not amygdala. Behav Pharmacol 8(4):331-338
32. Bach ME, Barad M, Son H, Zhuo M, Lu YF, Shih R, Mansuy I, Hawkins RD, Kandel ER (1999) Age-related defects in spatial memory are correlated with defects in the late phase of hippocampal long-term potentiation in vitro and are attenuated by drugs that enhance the cAMP signaling pathway. Proc Natl Acad Sci U S A 96(9):5280-5285
33. Ebadi M, Sharma S, Shavali S, El Refaey H (2002) Neuroprotective actions of selegiline. J Neurosci Res 67(3):285-289
34. Schulzer M, Mak E, Calne DB (1992) The antiparkinson efficacy of deprenyl derives from transient improvement that is likely to be symptomatic. Ann Neurol 32(6):795-798
35. Paterson IA, Zhang D, Warrington RC, Boulton AA (1998) R-deprenyl and R-2-heptyl-N-methylpropargylamine prevent apoptosis in cerebellar granule neurons induced by cytosine arabinoside but not low extracellular potassium. J Neurochem 70(2):515-523
36. Kiray M, Uysal N, Sonmez A, Acikgoz O, Gonenc S (2004) Positive effects of deprenyl and estradiol on spatial memory and oxidant stress in aged female rat brains. Neurosci Lett 354(3):225-228
37. Thomas T, McLendon C, Thomas G (1998) L-deprenyl: nitric oxide production and dilation of cerebral blood vessels. NeuroReport 9(11):2595-2600
38. Zeng YC, Bongrani S, Bronzetti E, Cadel S, Ricci A, Valsecchi B, Amenta F (1995) Effect of long-term treatment with L-deprenyl on the age-dependent microanatomical changes in the rat hippocampus. Mech Ageing Dev 79(2-3):169-185
39. Magyar K, Haberle D (1999) Neuroprotective and neuronal rescue effects of selegiline: review. Neurobiology (Bp) 7(2):175-190
40. Pitsikas N, Rigamonti AE, Cella SG, Sakellaridis N, Muller EE (2005) The nitric oxide donor molsidomine antagonizes age-related memory deficits in the rat. Neurobiol Aging 26(2):259-264
41. Fin C, da Cunha C, Bromberg E, Schmitz PK, Bianchin M, Medina JH, Izquierdo I (1995) Experiments suggesting a role for nitric oxide in the hippocampus in memory processes. Neurobiol Learn Mem 63(2):113-115
42. Liu P, Smith PF, Appleton I, Darlington CL, Bilkey DK (2004) Potential involvement of NOS and arginase in age-related behavioural impairments. Exp Gerontol 39(8):1207-1222